NMT2
Glycylpeptide N-tetradecanoyltransferase 2
Also known as: NMT2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O60551
- Gene
- NMT2
- Ensembl
- ENSG00000152465
- Chromosome
- 10
- Canonical length
- 498 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes one of two N-myristoyltransferase proteins. N-terminal myristoylation is a lipid modification that is involved in regulating the function and localization of signaling proteins. The encoded protein catalyzes the addition of a myristoyl group to the N-terminal glycine residue of many signaling proteins, including the human immunodeficiency virus type 1 (HIV-1) proteins, Gag and Nef. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]
Canonical amino-acid sequenceUniProt
498 residues, UniProt reviewed canonical sequence.
>O60551|NMT2
1 MAEDSESAAS QQSLELDDQD TCGIDGDNEE ETEHAKGSPG GYLGAKKKKK KQKRKKEKPN
61 SGGTKSDSAS DSQEIKIQQP SKNPSVPMQK LQDIQRAMEL LSACQGPARN IDEAAKHRYQ
121 FWDTQPVPKL DEVITSHGAI EPDKDNVRQE PYSLPQGFMW DTLDLSDAEV LKELYTLLNE
181 NYVEDDDNMF RFDYSPEFLL WALRPPGWLL QWHCGVRVSS NKKLVGFISA IPANIRIYDS
241 VKKMVEINFL CVHKKLRSKR VAPVLIREIT RRVNLEGIFQ AVYTAGVVLP KPIATCRYWH
301 RSLNPRKLVE VKFSHLSRNM TLQRTMKLYR LPDVTKTSGL RPMEPKDIKS VRELINTYLK
361 QFHLAPVMDE EEVAHWFLPR EHIIDTFVVE SPNGKLTDFL SFYTLPSTVM HHPAHKSLKA
421 AYSFYNIHTE TPLLDLMSDA LILAKSKGFD VFNALDLMEN KTFLEKLKFG IGDGNLQYYL
481 YNWRCPGTDS EKVGLVLQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NMT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 25 nTPM
Expression across tissuesHPA
Tissue
- thymus: 25 nTPM
- adipose tissue: 24 nTPM
- breast: 16 nTPM
- liver: 16 nTPM
- parathyroid gland: 16 nTPM
- ovary: 13 nTPM
Single-cell type
- sertoli cells: 205 nCPM
- hepatocytes: 194 nCPM
- mast cells: 190 nCPM
- adipocytes: 142 nCPM
- pancreatic duct cells: 128 nCPM
- differentiating spermatogonia: 99 nCPM
Immune cell
- T-reg: 30 nTPM
- naive CD4 T-cell: 22 nTPM
- NK-cell: 21 nTPM
- MAIT T-cell: 20 nTPM
- memory CD4 T-cell: 18 nTPM
- basophil: 15 nTPM
Brain region
- cerebellum: 32 nTPM
- cerebral cortex: 27 nTPM
- thalamus: 26 nTPM
- midbrain: 23 nTPM
- amygdala: 22 nTPM
- hippocampal formation: 21 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.45
- gnomAD pLI
- 0.24
- gnomAD missense Z
- 1.61
- DepMap mean gene effect
- 0.15
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- intracellular transport of virus
- N-terminal peptidyl-glycine N-myristoylation
- protein localization to membrane
- regulation of opsin-mediated signaling pathway
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Glycylpeptide N-tetradecanoyltransferase
- Acyl-CoA N-acyltransferase
- Glycylpeptide N-tetradecanoyltransferase, N-terminal
- Glycylpeptide N-tetradecanoyltransferase, C-terminal
- Glycylpeptide N-tetradecanoyltransferase, conserved site
- Myristoyl-CoA:protein N-myristoyltransferase, N-terminal domain
- Myristoyl-CoA:protein N-myristoyltransferase, C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NMT2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NMT2 as an antibody target. Whether an autoantibody or antibody against NMT2 could matter depends on whether native NMT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NMT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NMT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...